A Clinical Investigation Evaluating Wound Closure With OptiPulse™ Versus SOC in the Treatment of Non-Healing DFU's

NCT05193929 | Completed FDA Device

• 1 other identifier: DBC-PUL-02
• Study Type: interventional
• Target: 162
• Locations: 2 countries
• Sites: 19

Brief Summary

The purpose of this clinical investigation is to assess the safety and performance of Compedica's OptiPulse™ and to collect subject outcome data on the treatment of diabetic foot ulcers (DFU's) versus the standard of care (SOC). OptiPulse™ is designed to enhance blood circulation in the venules and arterioles. Fibracol Plus (or equivalent) is a collagen alginate dressing that is used as the primary dressing. Both products are 510(k) FDA cleared and will be used within the cleared intended use.

Conditions

Diabetic Foot Ulcer

Outcome Measures

Primary Outcomes (1)

• Percentage of index ulcers healed

  12 weeks

Secondary Outcomes (3)

• Time to Ulcer Healing

  12 weeks

• Percentage Area Change

  6 and 12 weeks

• Changes in wound quality of life from screening visit to end of study ( per W-QoL)

  12 weeks

Other Outcomes (1)

• Cost to Closure

  12 weeks

Study Arms (2)

OptiPulse™

EXPERIMENTAL

The OptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an offloaded and shin pumping unit and the other acts as pressure reducing footwear. Both active and non-active footwear should be worn to give balanced gait.

Device: OptiPulse™

Standard of care offloading device

ACTIVE COMPARATOR

Diabetic CAM boot

Device: Standard of Care offloading device

Interventions

OptiPulse™ DEVICE

TheOptiPulse™ is designed to enhance blood circulation in the venules and arterioles in subjects with diabetic foot ulcers of the lower extremities. OptiPulse™ is supplied as a pair of footwear. One side is fitted with an off loader and shin pumping unit, and the other acts as pressure reducing footwear.Both active and non-active footwear should be worn to give balanced gait

OptiPulse™

Standard of Care offloading device DEVICE

CAM boot

Standard of care offloading device

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• At least 18 years old, inclusive.
• Presence of a DFU, Wagner Grade 1 (see Appendix A for definitions) on the plantar or dorsal aspect of the foot, extending through the dermis provided it is below the medial aspect of the malleolus.
• The index ulcer will be the largest ulcer if two or more DFUs are present with the same Wagner grade and will be the only one evaluated in the study. If other ulcerations are present on the same foot, they must be more than 2 cm distant from the index ulcer.
• Index ulcer (i.e. current episode of ulceration) has been present for greater than 4 weeks prior to SV1 and less than 1 year, as of the date the subject consents for study.
• Index ulcer is a minimum of 0.8 cm2 and a maximum of 25 cm2 at SV1 and TV1.
• Within 3 months of SV1, adequate circulation to the affected foot, as documented by a dorsal transcutaneous oxygen measurement (TCOM) or a skin perfusion pressure (SPP) measurement of ≥ 30 mmHg, or an Ankle Branchial Index (ABI) between 0.7 and 1.3 within 3 months of SV1, using the affected study extremity. As an alternative arterial Doppler ultrasound can be performed evaluating for biphasic dorsalis pedis and posterior tibial vessels at the level of the ankle or a TBI (Toe Brachial Index) of \> 0.6 is acceptable.
• The target ulcer has been offloaded for at least 14 days prior to randomization.
• Females of childbearing potential must be willing to use acceptable methods of contraception (birth control pills, barriers or abstinence) during the course of the study and undergo pregnancy tests.
• Subject understands and is willing to participate in the clinical study and can comply with weekly visits.
• Subjects must have read and signed the IRB approved ICF before screening procedures are performed.

You may not qualify if:

• \. Index ulcer(s) deemed by the investigator to be caused by a medical condition other than diabetes.
• \. Index ulcer, in the opinion of the investigator, is suspicious for cancer and should undergo an ulcer biopsy to rule out a carcinoma of the ulcer.
• \. Index ulcer is overtly infected (i.e. purulent drainage). 4. Subjects with a history of more than two weeks of treatment with immune-suppressants (including systemic corticosteroids \>10mg daily dose), cytotoxic chemotherapy, or application of topical steroids to the ulcer surface within 1-month prior to first SV1, or who receive such medications during the screening period or who are anticipated to require such medications during the course of the study.
• \. Subjects on any investigational drug(s) or therapeutic device(s) within 30 days preceding SV1.
• \. History of radiation at the ulcer site (regardless of time since last radiation treatment).
• \. Index ulcer has been previously treated or will need to be treated with any prohibited therapies.
• \. Subjects with a previous diagnosis of HIV or Hepatitis C. 9. Presence of any condition(s) which seriously compromises the subject's ability to complete this study or has a known history of poor adherence with medical treatment.
• \. Osteomyelitis or bone infection of the affected foot as verified by x-ray within 30 days prior to the first screening visit. (In the event of an ambiguous diagnosis, the Principal Investigator will make the final decision).
• \. Subject is pregnant or breast-feeding. 12. Presence of diabetes with poor metabolic control as documented with an HbA1c \>12.0 within last 90 days.
• \. Subjects with end-stage renal disease as evidenced by a serum creatinine ≥3.0 mg/dL within 6 months of randomization. 14. Presence of active Charcot Neuroarthropathy to the affected limb. 15. Any wound located entirely on the medial or lateral border of the foot. 16. Any wound located between the 1st through 4th toe interspaces. 17. Index ulcer has reduced in area by 30% or more after 14 days of SOC from SV1 to the TV1/Randomization visit.

Sponsors & Collaborators

• Compedica Inc: lead
• Professional Education and Research Institute: collaborator

Study Sites (19)

Titan Clinical Research

Phoenix, Arizona, 85004, United States

Location

Felix Sigal

Los Angeles, California, 90010, United States

Location

Clemente Clinical Research

Los Angeles, California, 90033, United States

Location

ILD Research

Vista, California, 92083, United States

Location

Midland Florida clinical Research Center LLC

DeLand, Florida, 32720, United States

Location

Integral Clinical Trial Solutions

Homestead, Florida, 33030, United States

Location

Integral Clinical Trials Solutions

Pembroke Pines, Florida, 33026, United States

Location

Integral Clinical Trials Solutions

Tamarac, Florida, 33321, United States

Location

Viable Research Management

Las Vegas, Nevada, 89120, United States

Location

Foot Associates of New York

New York, New York, 10022, United States

Location

Foot & Ankle specialists of the Mid-Atlantic

Gastonia, North Carolina, 28054, United States

Location

Foot & Ankle Specialists of the Mid-Atlantic

Raleigh, North Carolina, 27609, United States

Location

Lower Extremity Institution of Research and Therapy (LEIRT)

Boardman, Ohio, 44512, United States

Location

Mt. Olympus Medical Research

Houston, Texas, 77054, United States

Location

Clinical Trials Network

Houston, Texas, 77074, United States

Location

Foot and Ankle Specialist of the Mid-Atlantic - Roanoke

Roanoke, Virginia, 24016, United States

Location

Foot and Ankle Specialist of the Mid-Atlantic - Salem

Salem, Virginia, 24153, United States

Location

Salem Research institute

Salem, Virginia, 24153, United States

Location

East Toronto Vascular Clinic

Toronto, Ontario, Canada

Location

MeSH Terms

Conditions

Diabetic Foot

Condition Hierarchy (Ancestors)

Diabetic Angiopathies; Vascular Diseases; Cardiovascular Diseases; Foot Ulcer; Leg Ulcer; Skin Ulcer; Skin Diseases; Skin and Connective Tissue Diseases; Diabetes Complications; Diabetes Mellitus; Endocrine System Diseases; Diabetic Neuropathies

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: December 13, 2021
• First Posted: January 18, 2022
• Study Start: December 15, 2021
• Primary Completion: December 1, 2025
• Study Completion: December 1, 2025
• Last Updated: March 19, 2026

Record last verified: 2026-03

Data Sharing

• IPD Sharing: Will not share

Locations

US (18); CA (1)